Biogen Idec Drug Patent Portfolio
Biogen Idec owns 1 orange book drug protected by 12 US patents Given below is the list of Biogen Idec's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12013403 | Compositions and methods for detection of SMN protein in a subject and treatment of a subject | 04 Mar, 2036 | Active |
| US10436802 | Methods for treating spinal muscular atrophy | 11 Sep, 2035 | Active |
| US9926559 | Compositions and methods for modulation of SMN2 splicing in a subject | 09 Jan, 2034 | Active |
| US8361977 | Compositions and methods for modulation of SMN2 splicing | 23 Dec, 2030 | Active |
| US8980853 | Compositions and methods for modulation of SMN2 splicing in a subject | 24 Nov, 2030 | Active |
| US9717750 | Compositions and methods for modulation of SMN2 splicing in a subject | 17 Jun, 2030 | Active |
| US7838657 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | 11 Jul, 2027 | Active |
| US10266822 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | 05 Dec, 2025 | Active |
| US8110560 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | 05 Dec, 2025 | Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines | 05 Sep, 2023 | Expired |
| US6210892 | Alteration of cellular behavior by antisense modulation of mRNA processing | 07 Oct, 2018 | Expired |
| US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions | 26 Dec, 2017 | Expired |
Latest Legal Activities on Biogen Idec's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biogen Idec.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8361977 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Mar, 2024 | US9717750 |
|
Email Notification
Critical
| 21 Mar, 2024 | US9717750 |
|
Patent Term Extension Certificate
Critical
| 18 Mar, 2024 | US8361977 |
|
Email Notification
Critical
| 11 Mar, 2024 | US8361977 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 11 Mar, 2024 | US8361977 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 05 Mar, 2024 | US8361977 |
|
Email Notification
Critical
| 29 Feb, 2024 | US10436802 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 29 Feb, 2024 | US9926559 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 29 Feb, 2024 | US10436802 |
|
Email Notification
Critical
| 29 Feb, 2024 | US9926559 |
|
Correspondence Address Change
Critical
| 01 Feb, 2024 | US8361977 |
|
Correspondence Address Change
Critical
| 01 Feb, 2024 | US8980853 |
|
Correspondence Address Change
Critical
| 01 Feb, 2024 | US9926559 |
|
Correspondence Address Change
Critical
| 01 Feb, 2024 | US10436802 |
Biogen Idec Drug Patents' Oppositions Filed in EPO
Biogen Idec drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 19, 2019, by Taylor Wessing Llp. This opposition was filed on patent number EP17203913A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17203913A | Jun, 2019 | Taylor Wessing LLP | Granted and Under Opposition |
Biogen Idec's Family Patents
Biogen Idec drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 33.3% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Biogen Idec Drug List
Given below is the complete list of Biogen Idec's drugs and the patents protecting them.
1. Spinraza
Spinraza is protected by 12 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12013403 | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
04 Mar, 2036
(11 years from now)
| Active |
| US10436802 | Methods for treating spinal muscular atrophy |
11 Sep, 2035
(10 years from now)
| Active |
| US9926559 | Compositions and methods for modulation of SMN2 splicing in a subject |
09 Jan, 2034
(9 years from now)
| Active |
| US8361977 | Compositions and methods for modulation of SMN2 splicing |
23 Dec, 2030
(6 years from now)
| Active |
| US8980853 | Compositions and methods for modulation of SMN2 splicing in a subject |
24 Nov, 2030
(6 years from now)
| Active |
| US9717750 | Compositions and methods for modulation of SMN2 splicing in a subject |
17 Jun, 2030
(5 years from now)
| Active |
| US7838657 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
11 Jul, 2027
(2 years from now)
| Active |
| US10266822 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
05 Dec, 2025
(1 year, 1 month from now)
| Active |
| US8110560 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
05 Dec, 2025
(1 year, 1 month from now)
| Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines |
05 Sep, 2023
(1 year, 1 month ago)
| Expired |
| US6210892 | Alteration of cellular behavior by antisense modulation of mRNA processing |
07 Oct, 2018
(6 years ago)
| Expired |
| US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
26 Dec, 2017
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spinraza's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List